---
title: "Phase 1 vs Phase 2 vs Phase 3 Trials: What Each Stage Actually Looks Like"
description: "A side by side comparison of Phase 1, Phase 2, and Phase 3 Parkinson's trials. Size, length, time commitment, and what families should expect at each stage."
canonical_url: "https://parkinsonspathways.com/learn/phase-1-vs-phase-2-vs-phase-3-trials"
date_published: 2026-05-01
date_modified: 2026-05-01
source: "Parkinson's Pathways"
---
# Phase 1 vs Phase 2 vs Phase 3 Trials: What Each Stage Actually Looks Like

Every Parkinson's clinical trial is tagged with a phase. Phase 1, Phase 2, Phase 3, sometimes Phase 4 or a hybrid like Phase 1 / Phase 2. Here is what each main phase actually looks like in practice for a participating family.

## Phase 1: Small, Short, Mostly About Safety

- Size: 20 to 100 participants.
- Length: weeks to a few months for the active phase.
- Visits: more frequent, because researchers watch closely for side effects.
- Placebo: often none, especially in early Phase 1 dose ranging studies.
- Where: usually a small number of academic medical centers, often only one or two.

## Phase 2: Medium Size, Longer, Starts Measuring Effect

- Size: a few hundred participants.
- Length: a few months to about a year, sometimes with an open label extension.
- Visits: defined schedule, often every few weeks at first and then monthly.
- Placebo: often placebo controlled. Treatment to placebo ratio is usually weighted toward treatment, commonly 2 to 1.
- Where: multiple sites, often a mix of academic medical centers and community research clinics.

## Phase 3: Large, Long, Designed to Get Approved

- Size: hundreds to several thousand participants.
- Length: one to three years or more.
- Visits: long term schedule, often monthly at first and then quarterly.
- Placebo: often placebo controlled or controlled against an existing standard treatment.
- Where: many sites in many countries. Phase 3 is often the easiest phase to find a participating site near you.

## A Side by Side Look

- What is being asked: Phase 1 is "is it safe?" Phase 2 is "does it work?" Phase 3 is "is it better than what we have?"
- Number of participants: small, medium, large.
- Total length: weeks to months, months to a year, one to three years or more.
- Placebo likelihood: often none, common, very common.
- Number of sites: small, medium, large and often international.

## Which Phase Should Your Family Look At

Phase tells you something about the kind of evidence behind a treatment, not whether the trial is right for you. Time commitment, location, and comfort with early stage data all matter.

Browse [Phase 1 trials](/trials?phases=Phase%201), [Phase 2 trials](/trials?phases=Phase%202), or [Phase 3 trials](/trials?phases=Phase%203) directly with the phase filter.

---

*Canonical: https://parkinsonspathways.com/learn/phase-1-vs-phase-2-vs-phase-3-trials*  
*HTML version: https://parkinsonspathways.com/learn/phase-1-vs-phase-2-vs-phase-3-trials*